ARTEMIDE-Lung04 – CPCNP metastático, PD-L1 ≥ 50% – 1ª linha | IDOR – Instituto D'Or de Pesquisa e Ensino array(64) { ["SERVER_SOFTWARE"]=> string(6) "Apache" ["REQUEST_URI"]=> string(92) "/instituto/idorensaio_clinico/artemide-lung04-cpcnp-metastatico-pd-l1-%E2%89%A5-50-1a-linha/" ["PHP_PATH"]=> string(24) "/opt/bitnami/php/bin/php" ["FREETDSLOCALES"]=> string(0) "" ["FREETDSCONF"]=> string(0) "" ["OPENSSL_ENGINES"]=> string(31) "/opt/bitnami/common/lib/engines" ["OPENSSL_CONF"]=> string(39) "/opt/bitnami/common/openssl/openssl.cnf" ["SSL_CERT_FILE"]=> string(52) "/opt/bitnami/common/openssl/certs/curl-ca-bundle.crt" ["CURL_CA_BUNDLE"]=> string(52) "/opt/bitnami/common/openssl/certs/curl-ca-bundle.crt" ["LDAPCONF"]=> string(42) "/opt/bitnami/common/etc/openldap/ldap.conf" ["GS_LIB"]=> string(43) "/opt/bitnami/common/share/ghostscript/fonts" ["MAGICK_CODER_MODULE_PATH"]=> string(60) "/opt/bitnami/common/lib/ImageMagick-6.9.8/modules-Q16/coders" ["MAGICK_CONFIGURE_PATH"]=> string(73) "/opt/bitnami/common/lib/ImageMagick-6.9.8/config-Q16:/opt/bitnami/common/" ["MAGICK_HOME"]=> string(19) "/opt/bitnami/common" ["PATH"]=> string(260) "/opt/bitnami/apps/wordpress/bin:/opt/bitnami/varnish/bin:/opt/bitnami/sqlite/bin:/opt/bitnami/php/bin:/opt/bitnami/mysql/bin:/opt/bitnami/letsencrypt/:/opt/bitnami/apache2/bin:/opt/bitnami/common/bin:/usr/local/sbin:/usr/local/bin:/usr/sbin:/usr/bin:/sbin:/bin" ["USER"]=> string(6) "daemon" ["HOME"]=> string(9) "/usr/sbin" ["SCRIPT_NAME"]=> string(10) "/index.php" ["QUERY_STRING"]=> string(0) "" ["REQUEST_METHOD"]=> string(3) "GET" ["SERVER_PROTOCOL"]=> string(8) "HTTP/1.0" ["GATEWAY_INTERFACE"]=> string(7) "CGI/1.1" ["REDIRECT_URL"]=> string(86) "/instituto/idorensaio_clinico/artemide-lung04-cpcnp-metastatico-pd-l1-≥-50-1a-linha/" ["REMOTE_PORT"]=> string(4) "4705" ["SCRIPT_FILENAME"]=> string(44) "/opt/bitnami/apps/wordpress/htdocs/index.php" ["SERVER_ADMIN"]=> string(15) "you@example.com" ["CONTEXT_DOCUMENT_ROOT"]=> string(34) "/opt/bitnami/apps/wordpress/htdocs" ["CONTEXT_PREFIX"]=> string(0) "" ["REQUEST_SCHEME"]=> string(4) "http" ["DOCUMENT_ROOT"]=> string(34) "/opt/bitnami/apps/wordpress/htdocs" ["REMOTE_ADDR"]=> string(12) "15.228.96.37" ["SERVER_PORT"]=> string(2) "80" ["SERVER_ADDR"]=> string(11) "172.26.1.14" ["SERVER_NAME"]=> string(13) "54.225.48.228" ["SERVER_SIGNATURE"]=> string(0) "" ["LD_LIBRARY_PATH"]=> string(410) "/opt/bitnami/sqlite/lib:/opt/bitnami/mysql/lib:/opt/bitnami/apache2/lib:/opt/bitnami/common/lib:/opt/bitnami/sqlite/lib:/opt/bitnami/mysql/lib:/opt/bitnami/apache2/lib:/opt/bitnami/common/lib:/opt/bitnami/varnish/lib:/opt/bitnami/varnish/lib/varnish:/opt/bitnami/varnish/lib/varnish/vmods:/opt/bitnami/sqlite/lib:/opt/bitnami/mysql/lib:/opt/bitnami/apache2/lib:/opt/bitnami/common/lib:/opt/bitnami/common/lib64" ["HTTP_X_RDWR_CDN_IP"]=> string(14) "216.73.216.186" ["HTTP_X_AMZ_CF_ID"]=> string(56) "UBHmFEWAazSW52Vr6OYCalgSDTR04pemsEZyObVyGZsXDOZyDi91Gw==" ["HTTP_ACCEPT_ENCODING"]=> string(7) "br,gzip" ["HTTP_VIA"]=> string(64) "2.0 bbf175c94294473684e8193e0dd6dd0e.cloudfront.net (CloudFront)" ["HTTP_USER_AGENT"]=> string(103) "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)" ["HTTP_REFERER"]=> string(125) "http://www.rededorsaoluiz.com.br/instituto/idor/ensaio_clinico/artemide-lung04-cpcnp-metastatico-pd-l1-%E2%89%A5-50-1a-linha/" ["HTTP_ACCEPT"]=> string(3) "*/*" ["HTTP_X_RDWR_APP_ID"]=> string(36) "ea503418-5fa7-4f96-8a49-00f2cc254acd" ["HTTP_X_RDWR_PORT_MM_ORIG_FE_PORT"]=> string(3) "443" ["HTTP_X_RDWR_PORT"]=> string(5) "21280" ["HTTP_X_RDWR_IP"]=> string(14) "216.73.216.186" ["HTTP_X_AMZN_TRACE_ID"]=> string(40) "Root=1-69ce27bc-7e374493642f40a57c01d666" ["HTTP_X_FORWARDED_PORT"]=> string(3) "443" ["HTTP_CONNECTION"]=> string(5) "close" ["HTTP_X_FORWARDED_PROTO"]=> string(4) "http" ["HTTP_X_FORWARDED_FOR"]=> string(45) "216.73.216.186, 141.226.105.208, 10.247.46.55" ["HTTP_X_REAL_IP"]=> string(12) "10.247.46.55" ["HTTP_X_FORWARDED_HOST"]=> string(25) "www.rededorsaoluiz.com.br" ["HTTP_HOST"]=> string(13) "54.225.48.228" ["SCRIPT_URI"]=> string(106) "http://54.225.48.228/instituto/idorensaio_clinico/artemide-lung04-cpcnp-metastatico-pd-l1-≥-50-1a-linha/" ["SCRIPT_URL"]=> string(86) "/instituto/idorensaio_clinico/artemide-lung04-cpcnp-metastatico-pd-l1-≥-50-1a-linha/" ["REDIRECT_STATUS"]=> string(3) "200" ["REDIRECT_SCRIPT_URI"]=> string(106) "http://54.225.48.228/instituto/idorensaio_clinico/artemide-lung04-cpcnp-metastatico-pd-l1-≥-50-1a-linha/" ["REDIRECT_SCRIPT_URL"]=> string(86) "/instituto/idorensaio_clinico/artemide-lung04-cpcnp-metastatico-pd-l1-≥-50-1a-linha/" ["FCGI_ROLE"]=> string(9) "RESPONDER" ["PHP_SELF"]=> string(10) "/index.php" ["REQUEST_TIME_FLOAT"]=> float(1775118268.63) ["REQUEST_TIME"]=> int(1775118268) }

ARTEMIDE-Lung04 – CPCNP metastático, PD-L1 ≥ 50% – 1ª linha

Home

ARTEMIDE-Lung04 – CPCNP metastático, PD-L1 ≥ 50% – 1ª linha

Home
Busque por todo o site:

Resumo:

Avaliar eficácia e segurança de rilvegostomig em comparação a pembrolizumabe.
População:
  • ≥18 anos;
  • CPCNPm estágio IV;
  • Expressão de PD-L1 no tumor em ≥ 50%;
  • Ausência de mutações sensibilizantes do EGFR e rearranjos de ALK e ROS1, além de outras mutações acionáveis para as quais haja terapias de 1L direcionadas aprovadas localmente;
  • Peso corporal mínimo de 30 kg;
  • ECOG 0 a 1.

ClinicalTrials.gov: NCT06868277

Patrocinador: AstraZeneca
Local: São Paulo, Salvador
Áreas: Oncologia - Câncer de Pulmão
Investigador Principal: Dra. Samira Mascarenhas (BA) e Dr. Felipe José Silva (SP)

Contato:

Bahia – BA e São Paulo (SP)
Instituição: IDOR Bahia e IDOR São Paulo
Informações: 11 94257-9076 (WhatsApp)
E-mail: nucleodecaptacao@idor.org
Mais Informações